Why choose our Private Equity and Venture Capital lawyers?
We are not only experts within our field and sectors, but we are supported by other specialist groups across our European network, from regulatory and commercial colleagues specialising in medical device, genomics and biopharma, IP, data privacy, cyber security, mobile payments, telecoms to FCA and fintech. Our cross-practice and cross-sector teams not only execute deals but help clients navigate and pivot through complicated regulatory and commercial issues in order to get the deal done.
Our Private Equity and Venture Capital teams advise predominantly in our sector focus areas: Technology, Media, Life Sciences and Financial Services. We act for disruptive companies, investment funds, management teams and debt providers operating in these highly regulated sectors across Europe.
In the TMT sector, we act across the broad spectrum of tech, including advising innovative data-led digital growth companies in some of Europe's most pre-eminent tech accelerators, on early stage rounds (including EIS and VCT) to advising on later stage development capital including venture debt, bridge financing and buy-outs/exits, whether via trade sale or IPO. In the Life Sciences sector our clients include IP-rich University spin-outs, mature biopharma and medical device companies to specialist Life Sciences funds.
Fieldfisher Venture Capital Wrap 2019
Fieldfisher advised on more than £220 million of venture capital and venture debt deals in 2019, led by brisk activity in the tech sector as well as robust interest in life sciences and leisure.Download
Latest private equity and VC news and views
Sign up to our email digest